Eli Lilly Hits All-Time High as JPMorgan Raises Price Target to $1,400

Eli Lilly stock hit an all-time high on July 8, after JPMorgan analyst Chris Schott raised the price target to $1,400 on July 7, representing approximately 17% upside from the July 6 close. The new target exceeds Wall Street's consensus of around $1,243. JPMorgan's bull case cites strong demand for GLP-1 products, including diabetes drug Mounjaro and weight-loss drug Zepbound, alongside robust pipeline growth. The bank projects second-quarter revenue of $20.7 billion and earnings per share of $8.85, exceeding consensus estimates. Multiple other banks have similarly raised targets, with Cantor Fitzgerald lifting its price objective to $1,350 and RBC Capital Markets maintaining an Outperform rating at $1,250.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments